Drugs / 202-CoV
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04982068 | Jul → Oct 2021 | COVID-19 | Shanghai Zerun Biotechnology Co.,Ltd | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04990544 | Jul 2021 → Apr 2022 | COVID-19 | Shanghai Zerun Biotechnology Co.,Ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 202-CoV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04982068 ↗ |
| Modality | Vaccine | “Recombinant SARS-CoV-2 Vaccine (CHO Cell)” NCT04982068 ↗ |
| Route | Intramuscular | “administered as 2 injections (i.m) at 28 days apart” NCT04982068 ↗ |